These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 32634436)

  • 1. Overexpression of ABCB1 and ABCG2 contributes to reduced efficacy of the PI3K/mTOR inhibitor samotolisib (LY3023414) in cancer cell lines.
    Wu CP; Hung CY; Lusvarghi S; Huang YH; Tseng PJ; Hung TH; Yu JS; Ambudkar SV
    Biochem Pharmacol; 2020 Oct; 180():114137. PubMed ID: 32634436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ABCB1 and ABCG2 Overexpression Mediates Resistance to the Phosphatidylinositol 3-Kinase Inhibitor HS-173 in Cancer Cell Lines.
    Wu CP; Hung CY; Hsieh YJ; Murakami M; Huang YH; Su TY; Hung TH; Yu JS; Wu YS; Ambudkar SV
    Cells; 2023 Mar; 12(7):. PubMed ID: 37048130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Voruciclib, a Potent CDK4/6 Inhibitor, Antagonizes ABCB1 and ABCG2-Mediated Multi-Drug Resistance in Cancer Cells.
    Gupta P; Zhang YK; Zhang XY; Wang YJ; Lu KW; Hall T; Peng R; Yang DH; Xie N; Chen ZS
    Cell Physiol Biochem; 2018; 45(4):1515-1528. PubMed ID: 29486476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression of ATP-Binding Cassette Subfamily G Member 2 Confers Resistance to Phosphatidylinositol 3-Kinase Inhibitor PF-4989216 in Cancer Cells.
    Wu CP; Murakami M; Hsiao SH; Chou AW; Li YQ; Huang YH; Hung TH; Ambudkar SV
    Mol Pharm; 2017 Jul; 14(7):2368-2377. PubMed ID: 28597653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Avapritinib: A Selective Inhibitor of KIT and PDGFRα that Reverses ABCB1 and ABCG2-Mediated Multidrug Resistance in Cancer Cell Lines.
    Wu CP; Lusvarghi S; Wang JC; Hsiao SH; Huang YH; Hung TH; Ambudkar SV
    Mol Pharm; 2019 Jul; 16(7):3040-3052. PubMed ID: 31117741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters.
    Fan YF; Zhang W; Zeng L; Lei ZN; Cai CY; Gupta P; Yang DH; Cui Q; Qin ZD; Chen ZS; Trombetta LD
    Cancer Lett; 2018 May; 421():186-198. PubMed ID: 29331420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human ABCB1 (P-glycoprotein) and ABCG2 mediate resistance to BI 2536, a potent and selective inhibitor of Polo-like kinase 1.
    Wu CP; Hsiao SH; Sim HM; Luo SY; Tuo WC; Cheng HW; Li YQ; Huang YH; Ambudkar SV
    Biochem Pharmacol; 2013 Oct; 86(7):904-13. PubMed ID: 23962445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reversal effect of FW-04-806, a macrolide dilactone compound, on multidrug resistance mediated by ABCB1 and ABCG2 in vitro and in vivo.
    Zhang Z; Ma C; Li P; Wu M; Ye S; Fu L; Xu J
    Cell Commun Signal; 2019 Sep; 17(1):110. PubMed ID: 31472682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CC-115, a Dual Mammalian Target of Rapamycin/DNA-Dependent Protein Kinase Inhibitor in Clinical Trial, Is a Substrate of ATP-Binding Cassette G2, a Risk Factor for CC-115 Resistance.
    Beebe J; Zhang JT
    J Pharmacol Exp Ther; 2019 Nov; 371(2):320-326. PubMed ID: 31455631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
    Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW
    Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ulixertinib (BVD-523) antagonizes ABCB1- and ABCG2-mediated chemotherapeutic drug resistance.
    Ji N; Yang Y; Lei ZN; Cai CY; Wang JQ; Gupta P; Xian X; Yang DH; Kong D; Chen ZS
    Biochem Pharmacol; 2018 Dec; 158():274-285. PubMed ID: 30431011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SIS3, a specific inhibitor of Smad3 reverses ABCB1- and ABCG2-mediated multidrug resistance in cancer cell lines.
    Wu CP; Murakami M; Hsiao SH; Liu TC; Yeh N; Li YQ; Hung TH; Wu YS; Ambudkar SV
    Cancer Lett; 2018 Oct; 433():259-272. PubMed ID: 30026175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selonsertib (GS-4997), an ASK1 inhibitor, antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells.
    Ji N; Yang Y; Cai CY; Lei ZN; Wang JQ; Gupta P; Shukla S; Ambudkar SV; Kong D; Chen ZS
    Cancer Lett; 2019 Jan; 440-441():82-93. PubMed ID: 30315846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ABCG2 Mediates Resistance to the Dual EGFR and PI3K Inhibitor MTX-211 in Cancer Cells.
    Wu CP; Hung CY; Murakami M; Wu YS; Chu YH; Huang YH; Yu JS; Ambudkar SV
    Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biological evaluation of non-basic chalcone CYB-2 as a dual ABCG2/ABCB1 inhibitor.
    Cai CY; Zhang W; Wang JQ; Lei ZN; Zhang YK; Wang YJ; Gupta P; Tan CP; Wang B; Chen ZS
    Biochem Pharmacol; 2020 May; 175():113848. PubMed ID: 32044354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human ATP-binding cassette transporters ABCB1 and ABCG2 confer resistance to histone deacetylase 6 inhibitor ricolinostat (ACY-1215) in cancer cell lines.
    Wu CP; Hsieh YJ; Murakami M; Vahedi S; Hsiao SH; Yeh N; Chou AW; Li YQ; Wu YS; Yu JS; Ambudkar SV
    Biochem Pharmacol; 2018 Sep; 155():316-325. PubMed ID: 30028995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Coexpression of ABCB1 and ABCG2 in a Cell Line Model Reveals Both Independent and Additive Transporter Function.
    Robinson AN; Tebase BG; Francone SC; Huff LM; Kozlowski H; Cossari D; Lee JM; Esposito D; Robey RW; Gottesman MM
    Drug Metab Dispos; 2019 Jul; 47(7):715-723. PubMed ID: 31048454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Novel Synthetic Dihydroindeno[1,2-b] Indole Derivative (LS-2-3j) Reverses ABCB1- and ABCG2-Mediated Multidrug Resistance in Cancer Cells.
    Guo C; Liu F; Qi J; Ma J; Lin S; Zhang C; Zhang Q; Zhang H; Lu R; Li X
    Molecules; 2018 Dec; 23(12):. PubMed ID: 30544754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A dual PI3 kinase/mTOR inhibitor BEZ235 reverses doxorubicin resistance in ABCB1 overexpressing ovarian and pancreatic cancer cell lines.
    Durrant DE; Das A; Dyer S; Kukreja RC
    Biochim Biophys Acta Gen Subj; 2020 Jun; 1864(6):129556. PubMed ID: 32061787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overexpression of ABCB1 Transporter Confers Resistance to mTOR Inhibitor WYE-354 in Cancer Cells.
    Wang J; Yang DH; Yang Y; Wang JQ; Cai CY; Lei ZN; Teng QX; Wu ZX; Zhao L; Chen ZS
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32092870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.